

P 81-45-961-7498

E mary@lexaly.jp

A 2-37-21 Katsuradai, Aoba-ku,
Yokohama, Japan, 227-0034

W www.lexaly.com

BILINGUAL SERVICES

Writing and translation of research papers, clinical trial protocols, English reports of Japanese advisory board meetings, English and Japanese feature articles

RECENT EXPERIENCE

Apr 2017 – Present Founder and Principal Medical Writer
Lexaly Communications (self-employed)

Nov 2013 – Mar 2017 Customer Education Specialist
Cactus Communications Japan

Apr 2005 – Nov 2013 Foreign News Analyst, English Journal Copyeditor,
Project Manager, Advisory Board Meeting Reporter, Publications Manager,
Medical Tribune, Inc.

Earlier positions in LinkedIn:

<https://www.linkedin.com/in/mary-nishikawa-medical-writing/>

HIGHLIGHTS

2023: Translation and copywriting of website: www.renatoscience.com.

2022: English report of Japanese KOL meeting for fezolinetant.
Japanese infographic of paper: <https://pubmed.ncbi.nlm.nih.gov/33646435/>.

2021 – 2023: Covering the Pharma Beat in Japan (Japanese & English).
White paper: Using RWE in Japan (registration required).

Features: Implementing decentralized clinical trials (Parexel website).

Clinical trials: Japan's next chapter (Reuters Events website).

The shift toward digital technology for clinical research (Medidata website)
and Reuters Events website.

2021: Phase 1 study protocol writer for sivopixant.

2021: Medical writer of published paper: Relugolix Phase 3 Clinical
Study. <https://pubmed.ncbi.nlm.nih.gov/34895700/>.

**2020 – 2021: Clinical study summaries and KOL meeting reports on
HIF-PH inhibitor.**

2020 Aug: Editorial reviewer: RNA-dependent RNA polymerase, RdRP, a
promising therapeutic target for cancer and potentially COVID-19.
<https://doi.org/10.1111/cas.14618>.

2020 Mar, Jun: Medical writer of published papers.
Thrombosis J 18, 10 (2020). <https://doi.org/10.1186/s12959-020-00223-0>
J Arrhythmia. 2020; 36: 395– 405. <https://doi.org/10.1002/joa3.12332>

2020 Jan-Feb: Technical review of inebilizumab CTD modules
(Japanese and English).

2020 Feb: English minutes of bilingual meeting on SARS-CoV-2.

2019 Feb: Japan Times interview.

2019 Jan-Apr: Protocol writer for phase 1 study: Hemophilia A Drug.

2018 Aug: English book editor: *Be Efficient in Sales* by Kiyoshi Sekine.

2018 Feb-May: Protocol writer for phase 1 / 2 study (Drug for NSCLC
tumors harboring EGFR mutations).

2018 Oct-Nov: Localization writer for COPD medical device software.

2017 Reporter, World Congress on Lung Cancer.

2017-2019, 2021, 2022 Invited speaker, Japan Respiratory Society.

CERTIFICATES AND WORKSHOPS

2020 Japan Medical Communicator's Workshop,
AMWA Meeting online

2019, 2020 DIA Communications Workshops

2018 FDA IND/NDA Course (DIA)

2017 ICMJE & CONSORT Updates (Tokyo U.)

2014 Data Management for Clinical Research

(Vanderbilt U.), Clinical Trials (Harvard edX),

2013 AMWA Core Curriculum, Pharma

Statistics in Medicine, Writing in the Sciences

(Stanford School of Med.)

Written Augmentation (Chicago U. Lectures in
Japan)

Others in LinkedIn: <https://www.linkedin.com/in/mary-nishikawa-medical-writing/>

DEGREES

Masters, Biochemistry, City College, City University
of New York

Bachelors, Biology, Adelphi University, New York

CERTIFICATES

Board Certified Editor in the Life Sciences

Japanese Language Proficiency Test Level 2

SKILLS

- MEDICAL WRITING AND EDITING (BOARD CERTIFIED)
- PROJECT & VENDOR MANAGEMENT
- CLINICAL TRIALS, PHARMACOVIGILANCE
- TRANSLATION (JAPANESE TO ENGLISH)
- BIostatISTICS
- DESIGN & FINE ARTS
- USER INTERFACE AND SOFTWARE TESTING
- AGILE DEVELOPMENT
- ONLINE TRAINING, WEBINARS
- RESEARCH PAPER WRITING FOR PUBLICATION
- PLAIN LANGUAGE WRITING, INFOGRAPHICS

AWARDS

- CACTUS EXCELLENCE AWARD

Multitasking and customizing content for delivery,
proposal writing, and use case stories

LEADERSHIP

Vice-Chair, Independent Business Committee,
American Chamber of Commerce: Interview in Japan
Today, June 2, 2020.